-$0.22 EPS Expected for NuCana (NCNA) This Quarter
Equities analysts expect NuCana (NASDAQ:NCNA) to announce earnings of ($0.22) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for NuCana’s earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.20). The business is expected to issue its next quarterly earnings results on Monday, January 1st.
Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for NuCana.
Separately, Zacks Investment Research cut shares of NuCana from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $21.00.
Hedge funds have recently made changes to their positions in the business. Alps Advisors Inc. purchased a new stake in NuCana in the 4th quarter worth $357,000. UBS Asset Management Americas Inc. lifted its stake in NuCana by 4.5% in the 4th quarter. UBS Asset Management Americas Inc. now owns 464,600 shares of the company’s stock worth $4,697,000 after purchasing an additional 19,800 shares in the last quarter. Sofinnova Management VIII L.L.C. lifted its stake in NuCana by 600.0% in the 4th quarter. Sofinnova Management VIII L.L.C. now owns 4,666,666 shares of the company’s stock worth $47,180,000 after purchasing an additional 4,000,000 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in NuCana by 40.1% in the 4th quarter. Alliancebernstein L.P. now owns 910,358 shares of the company’s stock worth $9,204,000 after purchasing an additional 260,358 shares in the last quarter. Institutional investors and hedge funds own 30.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “-$0.22 EPS Expected for NuCana (NCNA) This Quarter” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://theolympiareport.com/2018/04/16/0-22-eps-expected-for-nucana-ncna-this-quarter.html.
NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.